Cargando…

Recalcitrant primary cutaneous Rosai‐Dorfman disease. Efficacy of sirolimus and intralesional methylprednisolone

Sinus histiocytosis or Rosai‐Dorfman disease (RDD) is a rare disorder with severe lymphadenopathy and a limited clinical course, the aetiology of which is still controversial. The disease usually affects cervical nodes, with fever, polyclonal gammopathy, and leucocytosis with neutrophilia. Pure cuta...

Descripción completa

Detalles Bibliográficos
Autor principal: Tirado‐Sánchez, Andrés
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549808/
https://www.ncbi.nlm.nih.gov/pubmed/37799357
http://dx.doi.org/10.1002/ski2.273
_version_ 1785115400450605056
author Tirado‐Sánchez, Andrés
author_facet Tirado‐Sánchez, Andrés
author_sort Tirado‐Sánchez, Andrés
collection PubMed
description Sinus histiocytosis or Rosai‐Dorfman disease (RDD) is a rare disorder with severe lymphadenopathy and a limited clinical course, the aetiology of which is still controversial. The disease usually affects cervical nodes, with fever, polyclonal gammopathy, and leucocytosis with neutrophilia. Pure cutaneous involvement occurs as the only manifestation in only 3% of cases. Cutaneous RDD is often associated with infections, immunodeficiency, and autoimmune disorders. A 52‐year‐old patient presented with disseminated, recurrent, and relapsed pure cutaneous RDD that responded well to treatment with sirolimus and local infiltrations of methylprednisolone. The patient had multiple nonpainful nodular and tumour‐like lesions, histiocytic infiltrates with emperipolesis were observed on histologic examination, and positive immunohistochemistry for CD68, and S100. There is no standardised treatment, then the patient was treated with various therapies, including systemic steroids, chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone), radiotherapy, and other immunosuppressive treatments. Some lesions were treated surgically, resulting in recurrence. Sirolimus and local infiltration with methylprednisolone were tried as salvage treatments, the patient responded well, reducing the incidence of new lesions during follow‐up, and the size of the preexisting lesions.
format Online
Article
Text
id pubmed-10549808
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105498082023-10-05 Recalcitrant primary cutaneous Rosai‐Dorfman disease. Efficacy of sirolimus and intralesional methylprednisolone Tirado‐Sánchez, Andrés Skin Health Dis Case Reports Sinus histiocytosis or Rosai‐Dorfman disease (RDD) is a rare disorder with severe lymphadenopathy and a limited clinical course, the aetiology of which is still controversial. The disease usually affects cervical nodes, with fever, polyclonal gammopathy, and leucocytosis with neutrophilia. Pure cutaneous involvement occurs as the only manifestation in only 3% of cases. Cutaneous RDD is often associated with infections, immunodeficiency, and autoimmune disorders. A 52‐year‐old patient presented with disseminated, recurrent, and relapsed pure cutaneous RDD that responded well to treatment with sirolimus and local infiltrations of methylprednisolone. The patient had multiple nonpainful nodular and tumour‐like lesions, histiocytic infiltrates with emperipolesis were observed on histologic examination, and positive immunohistochemistry for CD68, and S100. There is no standardised treatment, then the patient was treated with various therapies, including systemic steroids, chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone), radiotherapy, and other immunosuppressive treatments. Some lesions were treated surgically, resulting in recurrence. Sirolimus and local infiltration with methylprednisolone were tried as salvage treatments, the patient responded well, reducing the incidence of new lesions during follow‐up, and the size of the preexisting lesions. John Wiley and Sons Inc. 2023-08-07 /pmc/articles/PMC10549808/ /pubmed/37799357 http://dx.doi.org/10.1002/ski2.273 Text en © 2023 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Tirado‐Sánchez, Andrés
Recalcitrant primary cutaneous Rosai‐Dorfman disease. Efficacy of sirolimus and intralesional methylprednisolone
title Recalcitrant primary cutaneous Rosai‐Dorfman disease. Efficacy of sirolimus and intralesional methylprednisolone
title_full Recalcitrant primary cutaneous Rosai‐Dorfman disease. Efficacy of sirolimus and intralesional methylprednisolone
title_fullStr Recalcitrant primary cutaneous Rosai‐Dorfman disease. Efficacy of sirolimus and intralesional methylprednisolone
title_full_unstemmed Recalcitrant primary cutaneous Rosai‐Dorfman disease. Efficacy of sirolimus and intralesional methylprednisolone
title_short Recalcitrant primary cutaneous Rosai‐Dorfman disease. Efficacy of sirolimus and intralesional methylprednisolone
title_sort recalcitrant primary cutaneous rosai‐dorfman disease. efficacy of sirolimus and intralesional methylprednisolone
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549808/
https://www.ncbi.nlm.nih.gov/pubmed/37799357
http://dx.doi.org/10.1002/ski2.273
work_keys_str_mv AT tiradosanchezandres recalcitrantprimarycutaneousrosaidorfmandiseaseefficacyofsirolimusandintralesionalmethylprednisolone